The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)
Open accessAbstract
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by dysregulated tubular epithelial cell growth, resulting in the formation of multiple renal cysts and progressive renal failure. To date, there is no effective treatment for ADPKD. The mammalian target of rapamycin (mTOR) is an atypical protein kinase and a central controller of cell growth and proliferation. We examined the effect of the mTOR inhibitor sirolimus (rapamycin) on renal functional loss and cyst progression in the Han:SPRD rat model of ADPKD. METHODS: Five-week-old male heterozygous cystic (Cy/+) and wild-type normal (+/+) rats were administered sirolimus (2 mg/kg/day) orally through the drinking water for 3 months. The renal function was monitored throughout the treatment phase, and rats were sacrificed thereafter. Kidneys were analysed histomorphometrically, and for the expression and phosphorylation of S6K, a well-characterized target of mTOR in the regulation of cell growth. RESULTS: The steady increase in BUN and creatinine in Cy/+ rats was reduced by 39 and 34%, respectively with sirolimus after 3 months treatment. Kidney weight and 2-kidney/total body weight (2K/TBW) ratios were reduced by 34 and 26% in sirolimus-treated Cy/+ rats. Cyst volume density was also reduced by 18%. Of importance, Cy/+ rats displayed enhanced levels of total and phosphorylated S6K. Sirolimus effectively reduced total and phosphorylated levels of S6K. CONCLUSION: We conclude that oral sirolimus markedly delays the loss of renal function and retards cyst development in Han:SPRD rats with ADPKD. Our data also suggest that activation of the S6K signalling pathway plays an important role in the pathogenesis of PKD. Sirolimus could be a useful drug to retard progressive renal failure in patients with ADPKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Self-citationGuba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
PKD2 , a Gene for Polycystic Kidney Disease That Encodes an Integral Membrane Protein
Mochizuki, T., Wu, G., Hayashi, T., Xenophontos, S. L., Veldhuisen, B., Saris, J. J., Reynolds, D. M., Cai, Y., Gabow, P. A., Pierides, A., et al. (1996) · Science · doi:10.1126/science.272.5266.1339 · Cited by 1,406
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042831 · Cited by 990
Dysregulation of the TSC-mTOR pathway in human disease
Inoki, K., Corradetti, M. N., & Guan, K.-L. (2005) · Nature Genetics · doi:10.1038/ng1494 · Cited by 972
Wilson, P. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022161 · Cited by 916
Dise, T. E. P. K. (1994) · Cell · doi:10.1016/0092-8674(94)90137-6 · Cited by 903
Polycystic kidney disease: The complete structure of the PKD1 gene and its protein
The International Polycystic Kidney Disease Consortium (1995) · Cell · doi:10.1016/0092-8674(95)90339-9 · Cited by 625
Genetics and Pathogenesis of Polycystic Kidney Disease
Igarashi, P., & Somlo, S. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000028643.17901.42 · Cited by 593
Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E., & Thomas, G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00212.x · Cited by 443
Rapamycin Markedly Slows Disease Progression in a Rat Model of Polycystic Kidney Disease
Tao, Y., Kim, J., Schrier, R. W., & Edelstein, C. L. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080660 · Cited by 391
Immunopurified Mammalian Target of Rapamycin Phosphorylates and Activates p70 S6 Kinase α in Vitro
Isotani, S., Hara, K., Tokunaga, C., Inoue, H., Avruch, J., & Yonezawa, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34493 · Cited by 336
Wang, X., Gattone, V., Harris, P. C., & Torres, V. E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121090 · Cited by 334
Lieberthal, W., Fuhro, R., Andry, C. C., Rennke, H., Abernathy, V. E., Koh, J. S., Valeri, R., & Levine, J. S. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.4.f693 · Cited by 270
Mathieu, O., Cruz‐Orive, L. M., Hoppeler, H., & Weibel, E. R. (1981) · Journal of Microscopy · doi:10.1111/j.1365-2818.1981.tb01200.x · Cited by 218
Saitoh, M., Pullen, N., Brennan, P., Cantrell, D., Dennis, P. B., & Thomas, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201745200 · Cited by 177
Delmas, P. (2004) · Cell · doi:10.1016/j.cell.2004.07.007 · Cited by 168
Khaleghpour, K., Pyronnet, S., Gingras, A., & Sonenberg, N. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4302 · Cited by 118
Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats
Torres, V. E., Sweeney, W. E., Wang, X., Qian, Q., Harris, P. C., Frost, P., & Avner, E. D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00952.x · Cited by 79
Molecular basis of polycystic kidney disease: PKD1, PKD2 and PKHD1
Harris, P. C. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200205000-00007 · Cited by 72
Therapies to Slow Polycystic Kidney Disease
Torres, V. E. (2004) · Nephron Experimental Nephrology · doi:10.1159/000079926 · Cited by 42
Cited by
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., Flask, C. A., Novick, A. C., Goldfarb, D. A., Kramer-Zucker, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509694103 · Cited by 808
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587
Autosomal dominant polycystic kidney disease: the last 3 years
Torres, V. E., & Harris, P. C. (2009) · Kidney International · doi:10.1038/ki.2009.128 · Cited by 590
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Self-citation
Metadata
- Authors
- Wahl, P. R., Serra, A. L., Le Hir, M., Molle, K. D., Hall, M. N., & Wüthrich, R. P.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-11
- Volume
- 21
- Issue
- 3
- Pages
- 598-604
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2152198679
- Cited by
- 287
- References
- 23
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.